Alnylam Pharmaceuticals
ALNY
#754
Rank
$23.44 B
Marketcap
$188.26
Share price
1.22%
Change (1 day)
47.34%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$8.69

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$8.69. In 2022 the company made an earnings per share (EPS) of -$9.29 a decrease over its 2021 EPS that were of -$7.20.

EPS history for Alnylam Pharmaceuticals from 2012 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$8.69-6.46%
2022-$9.2929.03%
2021-$7.20-3.36%
2020-$7.45-8.48%
2019-$8.147.67%
2018-$7.5639.74%
2017-$5.4112.94%
2016-$4.7938.84%
2015-$3.45-32.88%
2014-$5.14259.44%
2013-$1.43-31.25%
2012-$2.08

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.28-137.74%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$2.85-132.74%๐Ÿ‡ซ๐Ÿ‡ท France
$39.04-549.25%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.65 45.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.90-78.14%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.38-95.63%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.12-75.60%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
-$0.19-97.81%๐Ÿ‡บ๐Ÿ‡ธ USA